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Thiazolidinediones (TZDs), among which Rosiglitazone, are known agonists of the peroxisome-proliferator-activated receptor γ
(PPARγ)commonly usedfortreatmentofhyperglycemia. Arecently publishedarticledescribingacasereportonapatientaﬀected
by Fibrodysplasia Ossiﬁcans Progressiva (FOP) treated with Rosiglitazone has prompted interest for careful analysis of the rational
basis of such treatment. This article reviews the eﬀects of PPARγ agonists in relationship with various pathogenic steps that occur
during the course of FOP by reviewing the particularly rich literature on the eﬀects of Rosiglitazone, to underscore their relevance
to FOP and to consider possible adverse eﬀects.
1.FibrodysplasiaOssiﬁcans Progressiva
Fibrodysplasia Ossiﬁcans Progressiva (FOP) (MIM 135100)
is a rare and extremely disabling disorder, characterized by
congenital malformation of the great toes and progressive
heterotopic ossiﬁcation [1, 2].
Heterotopic ossiﬁcation generally starts in the infancy
and continues in an episodic and progressive way. Typically,
the disorder presents with alternate quiescent periods, that
sometimes last also years, and acute phases (ﬂareups)
through which ectopic bone formation at the level of axial
and appendicular skeleton occurs and causes progressive and
severe joint ankyloses and formation of an ectopic “second
skeleton” [3].
The molecular defect causing the disorder is a gain of
function mutation in the ACVR1/ALK2 gene, that encodes
a Type I receptor for bone morphogenetic proteins (BMPs)
[4]. The large majority of patients carry a heterozygous
recurrent mutation, c.617G>A, causing an R206H substi-
tution. This mutation aﬀects the protein Glycine Serine-
rich (GS) domain, which is highly conserved across species
and has regulatory function [4]. Much less frequently,
FOP is associated with substitution of other residues in
the same GS domain or in the kinase domain [5, 6].
The functional consequence of the ACVR1/ALK2 mutation,
accurately characterized by in vitro studies for the most
frequently occurring R206H mutation, is anomalous ligand-
independent activation and hyper-response to BMP ligands
of the SMAD-dependent signaling pathway [7–9]. Thus,
these results are consistent with the mechanism of ectopic
ossiﬁcation caused by a gain of function mutation in the
ACVR1/ALK2 gene.
The quite mild congenital malformation in the great
toes can be interpreted in the context of the complex
interplay of developmental pathways, including the BMP
pathway, controlling development of limb elements. The
most critical and still poorly understood point in the
pathogenic mechanism is the type of stimuli that trigger
ﬂareup episodes and subsequent ossiﬁcation.
Flareups seem to be induced by trauma, medical or
surgical or dental interventions, intramuscular injections,
and infections. However, in some cases ﬂareups start with no2 PPAR Research
apparent stimulus. The disorder is highly variable in term of
onset, frequency, and severity of ectopic ossiﬁcation episodes
[3].
Pathological ﬁndings described after analysis of bioptic
specimens from misdiagnosed patients have highlighted two
important points: the phases of tissue composition at the
sites of ﬂareup and the type of bone produced in ectopic
lesions [10–14].
Bone formation is preceded by the appearance of bumps
that very often cause misdiagnosis by erroneous attribution
oftheinitiallesiontocancerorotherdisorderslikeaggressive
juvenile ﬁbromatosis or lymphoedema [3]. The histological
analysis[10–14]showscharacteristicsofinﬂamedtissuewith
perivascular inﬁltration of B and T lymphocytes extending
towards the surrounding muscular tissue and inducing its
necrotic process. This initial phase is followed by an intense
ﬁbroproliferative reaction, vascularisation, and angiogenesis.
After the ﬁbroproliferative phase ectopic bone formation
takes place through a normal endochondral intermediate
phase. Mast cell inﬁltration is observed in all phases and is
particularly abundant in the initial phases, further support-
ing the inﬂammatory nature of the initial stimulus [13, 14].
FOP ectopic bone appears as a normal endochondrally
formed lamellar bone with normal bone marrow elements.
Radiological and scintigraphic characterization of ectopic
bone in 47 FOP patients showed characteristics of resistance,
stress response, and remodeling comparable to normal bone
in unaﬀected people [15].
Thus, an inﬂammatory stimulus that in some way
reachesamutatedreceptorandstimulatesahyper-responsive
signaling pathway are essential elements in the pathogenic
process. Many eﬀorts and expectations are directed to ﬁnd
approaches to interfere with the most critical steps of the
pathogenicmechanismthatcouldbeneﬁciallyaﬀectpatients’
quality of life.
Very recently an article that describes successful results
of treatment of an FOP patient with Rosiglitazone has been
published [16], which stimulates an in depth analysis of
possibleeﬀectsofsuchtreatmentinrelationshipwithvarious
pathogenic steps that occur during the course of FOP.
The aim of this article was to review a particularly
rich literature on the eﬀects of Rosiglitazone and try to
underscore their relevance to FOP.
2. Rosiglitazone
Rosiglitazone (ROSI) belongs to the class of Thiazolidine-
diones (TZDs) and has been approved as drug for treatment
of hyperglycemia [17]. Other TZD molecules are Troglita-
zone, ﬁrst approved drug in this class that was withdrawn
from the market because of severe drug-induced liver failure,
and Pioglitazone, presently available for therapeutic uses as
Rosiglitazone.
R o s i g l i t a z o n ei sm a i n l yu s e da sa no r a l l ya c t i v eh y p o -
glycemic agent for the treatment of noninsulin-dependent
d i a b e t e sm e l l i t u so rT y p e2D i a b e t e s( T 2 D ) .
2.1. Mechanism of Action: ROSI as an Antidiabetic Drug.
One of the characteristics of T2D is impaired response to
normal circulating insulin levels at target tissues (muscle,
liver, adipose tissue). Pancreatic beta cells partly compensate
this resistance by increasing their own mass and/or eﬃciency
ofinsulinsecretion,however,whenthiscompensatoryability
is insuﬃcient, hyperglycemia occurs. ROSI acts by the
highly selective activation of the Peroxisome-Proliferator-
Activated Receptor gamma (PPAR-γ), a ligand dependent
transcription factor that belongs to the family of nuclear
hormone receptors [17, 18]. PPAR-γ is expressed in tissues
that are key targets for insulin action such as adipose
tissue,skeletalmuscle,andliver.PPAR-γ activationpositively
regulates transcription of insulin responsive genes involved
in glucose control of synthesis, transport, and utilization,
thus contributing to restore sensitivity to insulin at target
organs and to glycemia control.
Because of its actions at diﬀerent levels, adverse eﬀects
such as appearance or worsening of cardiovascular events,




PPAR-γ, the transcription factor for which ROSI is a potent
and selective agonist, is involved in several diﬀerent physi-
ological and pathological processes such as diﬀerentiation,
inﬂammation, aging, obesity, infertility, and cancer [19–
21]. In particular it is essential for adipogenesis, glucose
homeostasis, and control of inﬂammation.
Three PPAR isotypes, with diﬀerent expression patterns,
are known.
(i) PPAR-α is expressed in tissues with high catalytic
activityoffattyacidsasliver,skeleton,cardiacmuscle,
renal cortex.
(ii) PPAR-δ has a wide expression pattern in particular in
tissues where it exerts control of fatty acid oxidation
as skin, brain, adipose tissue, muscle.
(iii) PPAR-γ, the most extensively studied, is highly
expressed in adipose tissue where it acts as the central
molecule for adipocytic diﬀerentation, in pancreatic
beta cells, vascular endothelial cells, and diﬀerent
c e l l si n v o l v e di ni m m u n er e s p o n s ea sm o n o c y t e s ,
macrophages, dendritic cells. PPAR-γ isoforms, dif-
fering for alternative promoters, and mRNA process-
ing, are reported [21].
The diﬀerent PPAR molecules share a four domain
structural oganization [19, 21]. The A/B NH2 terminal
domain, also named AF1 domain, is responsible for ligand-
independent transcriptional activity. The cDNA binding
domain is necessary for recognition of consensus sequences
in target gene regulatory regions, called PPAR response
elements(PPREs).TheDdomain,isessentialformodulation
of DNA binding thanks to binding of speciﬁc cofactors. A
transcriptional activation domain, named AF2, has the role
of both binding the ligand and mediating heterodimerizaton
with the obligate partner nuclear receptor for 9-cis retinoic
acid (RXR) [19, 21].PPAR Research 3
PPAR-γ transcriptional activity, either positive (transac-
tivating) or negative (transrepressing), is modulated both by
the interaction with a ligand and by posttranslational mod-
iﬁcations. Interaction with the ligand induces heterodimer-
ization with RXR and DNA binding. The simultaneous
release of repressor cofactors and recruitment of coactivators
also occur. PPAR-γ can interact with diﬀerent endogenous
ligands, such as fatty acid oxidized metabolites and 15-
deoxi-D-prostaglandine [22, 23], or exogenous ligands as
ﬂavonoids, linoleic or eicopentanoic or decoesanoic acids
present in the diet, and synthetic molecules as the TZD class
molecules ROSI, Pioglitazone, and Troglitazone [24].
PPAR-γ phosphorylation at speciﬁc residues, Ser 82/112
and Ser 84 in the AF1 domain, by diﬀerent kinases (ERK,
JNF-MAPK, AMPK), has a negative eﬀect on transcriptional
activation both ligand-dependent or independent [19, 21].
Another mechanism of transcriptional repression is due
to ligand-dependent sumoylation at the ligand-interaction
domain of PPAR-γ. Sumoylation causes formation of a
complex including PPAR-γ, a nuclear receptor corepressor
(NcoR) and histone deacetylase-3 (HDAC3). This complex
can be localized at PPREs in promoters of proinﬂammatory
genes related to the NFκB that are therefore repressed
[25].
3.1. PPAR-γ as an Anti-Inﬂammatory Molecule. PPAR-γ is
normallyexpressedinantigenpresentingcellsintheimmune
system, as monocytes, macrophages, and dendritic cells
[26–28]. Treatment of these cells with PPAR-γ agonists
such as TZDs causes suppression of inﬂammatory cytokines
production [29, 30]. Accordingly, analysis of gene expression
proﬁle in murine macrophages showed that PPAR-γ exerts
a general repressive action on a wide range of target genes
inducible by LPS or Interferon gamma (IFNγ)[ 31].
Generation of PPAR-γ conditional knock out mice in
macrophages further underscored its importance in control
of inﬂammation and oxidative metabolism [32].
Macrophages represent a ﬁrst line defense against
pathogens and, in response to microenvironment stimuli,
may become activated and diﬀerentiate by diﬀerent ways.
The classic activation is induced by Interferon-γ and pro-
motes a proinﬂammatory response to elimininate pathogens
[22]. An alternative activation pathway induced by cytokines
like IL-4 and IL-13, leads to a diﬀerent phenotype with an
important role in control and limitation of the inﬂammatory
response and tissue damage repair [22]. PPAR-γ is involved
in such alternative maturation process and therefore plays an
important anti-inﬂammatory role.
Other evidences underscore the anti-inﬂammatory role
of PPAR-γ. Animal models of inﬂammatory and autoim-
mune disorders as asthma, rheumatoid arthritis, multiple
sclerosis, and type 2 diabetes associated nephropathy [24, 25,
33], has highlighted the eﬃcacy of treatment with PPAR-γ
agonists in improving several signs associated with these
diseases. As an example, Pioglitazone results equally eﬃcient
as common treatments with corticosteroids for murine
models of asthma [33]. Pioglitazone and ROSI reduce
bone erosion secondary to inﬂammation in rat models of
rheumatoid arthritis [34] .T h e s es t u d i e sh a v ep r o v i d e dt h e
proof of principle for the use of PPAR-γ agonists in clinical
trials for treatment of multiple sclerosis and ulcerative colitis
and for already approved trials for treatment of patients with
rheumatoid arthritis and asthma [35–37].
Together with the above evidences, a common PPAR-γ
(Pro12Ala) nonsynonymous polymorphism that causes sub-
stitution of the conserved Pro12 residue in the ligand-
independent DNA binding domain and other less common
variants have been evaluated in association studies and also
investigated by functional studies [38]. The variant protein
shows diﬀerential activation of target genes with respect to
the wild type protein. Moreover a protective role of the
Pro12Ala variant was reported in (a) patients with multiple
sclerosis who show a disease later onset [39]; (b) male
patients with coronary artery disease who show less severe
and less generalized atherosclerosis with reduced morbidity
and mortality of cardiovascular events [40]; (c) patients with
type 2 diabetes who show higher insulin sensitivity [40].
Besides mediating the antidiabetic and anti-
inﬂammatory eﬀects of TZD agonists, PPAR-γ was also
reported as a target of 5-aminosalicylic acid (5-ASA) anti-
inﬂammatory eﬀects in an animal model of inﬂammatory
bowel disease [41].
3.2. PPAR-γ: Adipogenesis versus Osteogenesis. Osteoblasts
and adipocytes share common progenitors, mesenchymal
stem cells.
PPAR-γ expression is early induced by diﬀerent key fac-
torsintheadipogenesispathwayandisconsideredthemaster
transcriptional regulator of adipogenesis [42]. Fibroblastic
cell lines start adipogenic diﬀerentiation after transfer of
PPAR-γ cDNA and murine myoblasts transdiﬀerentiate to
mature adipocytes [43]. Phenotypic conversion of these
cells to adipocytes is accompanied by induction of genes
responsible for metabolism and secretion of fatty acids,
tryglyceridesynthesis,andtransportoflongchainfattyacids.
Generation of PPAR-γ knock out mouse models were
critical for deﬁning the eﬀects of changes in PPAR-γ levels
in vivo.
Null homozygous mice showed lethality during embryo
development at 10.5–11.5dpc because of placental dysfunc-
tion [43]. Interestingly, analysis of mice heterozygous for
the null allele [43] which showed normal development and
growth on a standard diet, also showed protection from
obesity and insulin resistance under high fat content diet,
that were abrogated by treatment with PPAR-γ agonists.
The protective state in heterozygotes was associated with a
nearly 2-fold higher leptin expression under high fat diet.
Studies on these mice to examine the eﬀect of PPAR-γ
deﬁciency in bone metabolism [44] showed that Embry-
onal Stem Cells from homozygous nulls were unable to
undergo adipogenesis, while osteogenesis was spontaneously
occurring in the absence of osteogenic inducers. Treatment
of the same cells with PPAR-γ restored adipogenesis and
decreased osteogenesis indicating a coordinated opposite
regulation of the two processes by PPAR-γ. The observa-
tion of heterozygous mice conﬁrmed an apparent normal
growth under standard diet, including the length of trunk
and long bones. However, radiological and densitometric4 PPAR Research
analyses show a 40% increase of trabecular bone mass and
concomitant reduction of marrow adipocyte number in long
bones and vertebrae. Accordingly, primary bone marrow
cellsfromheterozygotesshowedincreasedosteoblastogenesis
in the absence of diﬀerentiating agents, with upregulation of
key molecules for osteoblast diﬀerentiation, Runx2, osterix,
and LRP5. Although the switching mechanism between the
adipogenic and osteogenic diﬀerentiation pathways from
common progenitors was not fully clariﬁed, these studies
clearly indicated that PPAR-γ acts as a potent suppressor of
commitment and diﬀerentiation to the osteoblastic lineage.
Another contribution by the study of PPAR-γ deﬁcient mice





Another mouse model, the PPAR-γhyp/hyp, in which a
hypomorphic mutation at the PPAR-γ locus causes absence
of PPAR-γ expression in white adipose tissue (WAT), has
highlighted the contribution of PPAR-γ to bone homeostasis
[45]. The homozygous mice, which are severely lipodys-
trophic, showed increase of bone mineral density, bone area
and bone content, and bone trabecular thickness, demon-
strating that the decrease in PPAR-γ activity in fat enhances
bone formation. Increased osteoblast activity was consistent
withincreasedexpressionofosteoblast-speciﬁctranscription
factors and markers. In association to lipodystrophy, strong
reduction of leptin levels was observed, known to enhance
bone formation in mice and humans [46]. These mice also
exhibited increased osteoclast activity (see following section)
and extramedullary hematopoiesis probably explained by
bone marrow space limitation.
3.3. PPAR-γ and Osteoclastogenesis. Considering the ob-
served reduced bone mass after treatment with TZD PPAR-
γ agonists, both in animal models and in clinical studies in
diabetic human patients, the question whether these drugs,
besidesaﬀectingosteoblastogenesis,alsoaﬀectosteoclastoge-
nesis also arises. Osteoclasts are multinucleated cells derived
from hematopoietic precursors, contrary to osteoblasts that
derive from mesenchymal stem cells.
As mentioned above, PPAR-γhyp/hyp mice showed
increased osteoclast activity documented by increased
expression of genes typical of the osteoclastic lineage,
tartrate-resistant acid phosphatase (Trap) and cathepsin K
(CathK)[ 45].
On the other hand, mice generated with conditional
knock out of PPAR-γ in hematopoietic and endothelial
cells showed evident splenomegaly with megakaryocyte
accumulation, extramedullary hematopoiesis, pale bones,
increased bone volume with reduced marrow cavity [47].
Afterhematopoiesisestablishedinspleenintheplaceofbone
marrow, the mice showed normal hematopoiesis with nor-
mal activation and expression of speciﬁc genes and markers.
Reduction of marrow cavity and increase of bone volume
s u g g e s t e dad e f e c t i v eb o n er e m o d e l i n gb e c a u s eo fd e f e c t
of osteoclast function. Osteoclasts were reduced in number
while osteoblasts were normally present. Early osteoclast
markers, such as tartrate-resistant acid phosphatase (TRAP),
calcitonin receptor (Calcr), carbonic anhydrase 2 (Car2),
cathepsin K (Ctsk), resulted defective due to lack of RANKL
direct transcriptional activation by PPAR-γ and consequent
defect of an essential pathway for diﬀerentiation of precursor
cells to mature osteoclasts [47] .T r e a t m e n tw i t hR O S Io f
progenitor cells from wild type mice led to stimulation of
osteoclast production, that did not take place when cells
were taken from PPAR-γ defective mice. The defect of the
RANKL pathway appeared associated with signaling through
c-fos, since the diﬀerentiation block could be released when
the mutant cells were infected with a viral vector expressing
exogenous c-fos cDNA. The extramedullary hematopoiesis
in the mutant mice could be corrected by transplantation
of bone marrow from normal mice, whereas the reverse
transplantation of bone marrow from PPAR-γ mutant
mice to normal mice caused appearance of extramedullary
hematopoiesis.
In summary, although with some contradiction in pub-
lished data (increased osteoclast activity in [45]v e r s u sd e f e c -
tive osteoclast activity in [47]), several evidences support the
involvementofPPAR-γ inosteoclastdiﬀerentiationandbone
remodeling.
3.4. Rosiglitazone and Bone: Eﬀect of Treatment in Animal
Models. The eﬀect of ROSI on bone metabolism has been
studied in vivo in animals to verify possible adverse eﬀects.
The examination of the in vivo eﬀect of ROSI adminis-
tration on the skeletons of adult (6 months old) male non-
diabetic C57BL/6 mice [48] showed decrease in total body
bone mineral density. Analysis by micro-CT demonstrated a
signiﬁcantlossofboneandchangesinseveralmorphometric
parameters of bone microarchitecture. Histomorphometric
analysis of the trabecular bone of the proximal tibia revealed
increase of fat content and number of adipocytes, accompa-
nied by a decrease in osteoblast surface and/or their activity.
These features were associated with decreased mRNAs for
osteoblast-speciﬁc transcription factors Dlx5 and Runx2 and
theosteoblast-speciﬁcmarkerCol1A1.IncontrastthemRNA
for the adipocyte-speciﬁc fatty acids binding protein aP2 was
increased.
Another article described the eﬀect of treatment of adult
(5 months old) male and female mice with rosiglitazone,
providing other informations on the mechanism of bone
loss [49]. A decrease in vertebral bone mineral density was
accompanied by increased marrow fat in both vertebral
and femoral bone. An increased number of adipocytes and
concomitant reduced number of osteoblasts were observed.
When mesenchymal stem cells (MSCs) from mice were
studied,nodiﬀerenceinMSCnumberwasfoundwhenROSI
treated mice were compared with untreated. ROSI had an
inhibitory eﬀect on osteoblastogenesis either when added in
early MSC cultures, that is, early multipotent progenitors, or
when added some days later, that is, when MSC had formed
colonies with mixed adipocyte and osteoblast diﬀerentiated
cells. In this latter case, when MSCs had become later
bipotent precursors, ROSI induced a displacement from
osteogenesis to adipogenesis. In further later diﬀerentiated
stages or in mature osteoblasts ROSI had no eﬀect.PPAR Research 5
Morphologic changes in bone and cell diﬀerentiative
potential were accompanied by changes in markers speciﬁc
of bone development, as Runx2, Osterix, Col1A1,a n d
osteocalcin, in favor of markers speciﬁc of adipogenesis.
3.5. Rosiglitazone: Eﬀect of Treatment in Humans. ROSI is
approved and currently utilized as antidiabetic drug in
patients aﬀected by type 2 diabetes. Data on eﬃcacy and
adverse events are available in large studies in which, besides
evaluatingglycemiccontrol,themostfrequentadverseevents
are reported: risk of cardiovascular events, weight gain, ﬂuid
retention and bone fracture. We focus especially on the
risk of bone fractures since other adverse events are more
connected with diabetes complications while the eﬀect on
bone metabolism has a direct relevance to FOP disease.
A large comparative study in which participated 500
centers in North America, Canada, and Europe, known as A
Diabetes Outcome Progression Trial (ADOPT), involved an
initial group of 4360 patients [50]. This study was designed
to compare monotherapy with ROSI with therapy with
metformin or glyburide.
The ﬁrst published results of ADOPT [51]r e p o r t e d
comparable eﬃcacy for the three drugs in term of control
of glycemia, with greater durability of glycemic control
in ROSI treated patients. Expected adverse events were
described: in particular for ROSI, weight gain, increased
LDL cholesterol, increased frequency of edema, reduction of
hematocritandCreactiveproteinlevel.Theauthorsreported
as unexpected a higher rate of fractures in females and
not in males (humerus, hand, foot), in the group receiving
rosiglitazone compared to metformin and glyburide [51].
A speciﬁc analysis of increased risk of fractures within the
ADOPT study reported that the diﬀerence among the three
groups of treatment was evident after one year and that
fractures occurred in pre- and postmenopause women in
limbs, not in hips or vertebrae [52]. Similar data were
obtained by another clinical multicentric study, known as
Rosiglitazone evaluated for cardiovascular outcomes in oral
agent combination therapy for type 2 Diabetes (RECORD),
designedtomonitorcardiovascularadverseevents.Increased
risk of fractures, especially in women, limited to upper and
lower limb distal parts, was described [53].
In a more recent study, the eﬀect of Pioglitazone and
ROSI was evaluated in a group of 1819 male and female
over 40 years old patients who underwent bone fracture
and TZD drug exposure [54]. The conclusion was that
the risk of fracture was signiﬁcantly higher during periods
of exposure to thiazolidinediones (both rosiglitazone and
pioglitazone) compared with unexposed periods. This risk
was proportional to duration of treatment and, contrary
to the previously cited articles, equal for females and
males.
Aconﬁrmationofriskofbonefractureinpatientstreated
with TZD drugs is reported in a recently published article
describing results of a cross-sectional study [55].
Another article by the group of authors who participated
in the ADOPT study, described results of measures of bone
biomarkers. Although not providing conclusive explanation
for the clinical ﬁndings, it would suggest an eﬀect of TZD
drugs primarily on increased bone resorption [56]. The
same authors state that further long-term studies will be
necessary to understand the mechanisms responsible for
TZD-related bone fractures and the consequent possible
preventive intervention to limit or abolish this adverse event.
4. Conclusions
FOP is one of the most disabling disorders of heterotopic
ossiﬁcation, considered as a “stem-cell disease” in which
progenitor cells harbouring a mutated ACVR1/ALK2 gene,
undergo a process of endochondral ossiﬁcation in response
to a mandatory inﬂammatory trigger. The identity of such
cells is still not completely understood and it is likely
that both resident progenitor cells of endothelial origin
and circulating hematopoietic stem-cells contribute to the
heterotopic bone formation [57, 58].
Keeping in mind these aspects of FOP pathogenesis, the
biological rationale of the use of ROSI in the treatment of
FOP is mainly based on the potent inducing eﬀect of ROSI
and, in general, TZD drugs, on the PPAR-γ transcription
factor.
The anti-inﬂammatory properties of PPAR-γ can sig-
niﬁcantly counteract the inﬂammatory stimuli responsible
for acute phases of the disease preliminary to ossiﬁcation
episodes. Moreover, a relevant PPAR-γ eﬀect on bone
diﬀerentiation and metabolism, based on the ability to
trigger and switch diﬀerentiation of progenitor cells towards
adipogenesis at the expense of osteogenesis, and possibly on
mechanisms involving osteoclast-mediated bone resorbtion,
is also taking place.
Whether rosiglitazone, due to both anti-inﬂammatory
eﬀects and eﬀects on ossiﬁcation pathways, can be a better
treatment than commonly used glucocorticoids or other
anti-inﬂammatory drugs might be deduced from results of
carefully designed clinical experimentation that should take
into account potential beneﬁt and undesired eﬀects. ROSI
is a well known antidiabetic drug for which a number of
adverse eﬀects have been widely described in the scientiﬁc
literature. Therefore, these have to be carefully considered
ﬁrst in term of awareness and then in term of ability to limit
and control such adverse events when proposing ROSI as a
potential treatment of FOP.
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